SARS-CoV-2 Spike Trimer Protein, His Tag (KP.3) (MALS verified)

Numéro de produit/spécification
Prix
Availability
Qté
SPN-S522e-100ug
$472.00
In Stock - Delivery in 1-2 business days
SPN-S522e-1mg (500ug X 2)
$2,940.00
In Stock - Delivery in 1-2 business days
SPN-S522e
Montant du produit :
$ 0
0
Ajouter au panier
Suggestion de nouveau produit Request Quote
Contact Us
Contact Us
Montant du produit:
$ 0
0
Ajouter au panier
  • Détails du produit
  • Affichage des données
  • Reviews & Citations
  • Important Statement
  • Resources
Synonyms

Spike, S protein, Spike glycoprotein, S glycoprotein

Source

SARS-CoV-2 Spike Trimer Protein, His Tag (KP.3) (SPN-S522e) is expressed from human 293 cells (HEK293). It contains AA Val 16 -Pro 1213 (Accession # QHD43416.1 (T19I, R21T, LPP24-26Del, A27S, S50L, H69del, V70del, V127F, G142D, Y144del, F157S, R158G, N211del, L212I, V213G, L216F, H245N, A264D, I332V, G339H, K356T, S371F, S373P, S375F, T376A, R403K, D405N, R408S, K417N, N440K, V445H, G446S, N450D, L452W, L455S, F456L, N460K, S477N, T478K, N481K, V483del, E484K, F486P, Q493E, Q498R, N501Y, Y505H, E554K, A570V, D614G, P621S, H655Y, N679K, P681R, N764K, D796Y, S939F, Q954H, N969K, V1104L, P1143L, R683A, R685A, F817P, A892P, A899P, A942P, K986P, V987P)). The recombinant protein is expressed from human 293 cells (HEK293) with T4 fibritin trimerization motif and a polyhistidine tag at the C-terminus. Proline substitutions (F817P, A892P, A899P, A942P, K986P, V987P) and alanine substitutions (R683A and R685A) are introduced to stabilize the trimeric prefusion state of SARS-CoV-2 S protein and abolish the furin cleavage site, respectively.

Predicted N-terminus: Val 16

Molecular Characterization

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 137.7 kDa. The protein migrates as 150-180 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

The protein is designed as a trimer.

Endotoxin

Less than 1.0 EU per μg by the LAL method / rFC method.

Purity

>90% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

Formulation

Lyophilized from 0.22 μm filtered solution in 0.1 M Sodium citrate, pH5.5 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Shipping and Storage

This product is shipped at ambient temperature.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.

Introduction de fond

The spike protein of SARS-CoV-2 variant KP.3, a sublineage of Omicron JN.1, facilitates viral entry by binding the human ACE2 receptor through its receptor-binding domain. KP.3 carries characteristic mutations, including changes in the N-terminal and receptor-binding domains, that may enhance transmissibility and immune evasion. These alterations are under close surveillance for their potential impact on vaccine effectiveness, therapeutic antibody binding, and the ongoing evolution of SARS-CoV-2 in the global population.